Review
doi: 10.1007/978-3-642-01222-8_5.
Sorafenib
Affiliations
- PMID: 20072831
- DOI: 10.1007/978-3-642-01222-8_5
Item in Clipboard
Review
Sorafenib
Recent Results Cancer Res.
2010.
Abstract
Sorafenib (BAY 43-9006, Nexavar) is a novel oral kinase inhibitor that targets multiple tyrosine kinases in vivo and in vitro. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the raf-ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3). Sorafenib was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer. Multiple clinical trials are undertaken to further investigate the role of sorafenib alone or in combination for the treatment of various tumor entities.
Similar articles
-
Sorafenib: targeting multiple tyrosine kinases in cancer.Recent Results Cancer Res. 2014;201:145-64. doi: 10.1007/978-3-642-54490-3_8. Recent Results Cancer Res. 2014. PMID: 24756790 Review.
-
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.Drugs Today (Barc). 2005 Dec;41(12):773-84. doi: 10.1358/dot.2005.41.12.937959. Drugs Today (Barc). 2005. PMID: 16474853 Review.
-
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov. 2006 Oct;5(10):835-44. doi: 10.1038/nrd2130. Nat Rev Drug Discov. 2006. PMID: 17016424 Review.
-
Sorafenib: delivering a targeted drug to the right targets.Expert Rev Anticancer Ther. 2007 May;7(5):617-26. doi: 10.1586/14737140.7.5.617. Expert Rev Anticancer Ther. 2007. PMID: 17492926 Review.
-
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4. Gastroenterol Clin Biol. 2008. PMID: 18341970 French. No abstract available.
Cited by
-
Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta-analysis.JGH Open. 2023 Dec 13;7(12):832-840. doi: 10.1002/jgh3.12999. eCollection 2023 Dec. JGH Open. 2023. PMID: 38162860 Free PMC article. Review.
-
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.World J Gastroenterol. 2014 Jun 28;20(24):7914-25. doi: 10.3748/wjg.v20.i24.7914. World J Gastroenterol. 2014. PMID: 24976727 Free PMC article.
-
Targeting angiogenesis in metastatic breast cancer.Oncologist. 2012;17(8):1014-26. doi: 10.1634/theoncologist.2012-0043. Epub 2012 Jul 27. Oncologist. 2012. PMID: 22843553 Free PMC article.
-
Pan-cancer analysis of the prognosis and immunological role of AKAP12: A potential biomarker for resistance to anti-VEGF inhibitors.Front Genet. 2022 Aug 30;13:943006. doi: 10.3389/fgene.2022.943006. eCollection 2022. Front Genet. 2022. PMID: 36110213 Free PMC article.
-
Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression.Cell Death Discov. 2022 Jun 9;8(1):281. doi: 10.1038/s41420-022-01073-7. Cell Death Discov. 2022. PMID: 35680841 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous